The AML developed after 44 months on dabrafenib, and advanced sequencing demonstrated monosomy 7, BRAF V600E, NRAS, KRAS, and EZH2 mutations as well as a RUNX1:POU2F2 fusion. The gene discussed is BRAF; the disease is acute myeloid leukemia.